Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer

Eligibility Criteria:

* Cytologically or histologically confirmed "COX dependent" non-small cell lung cancer.
* COX dependency is defined by change in urinary PGE-M levels following a "run-in" phase of celecoxib.
* Previous treatment with ≤2 different chemotherapy regimens one of which must have been platinum-based (cisplatin or carboplatin) chemotherapy.
* Age ≥18 years
* ECOG PS 0, 1 or 2.
* Measurable or evaluable disease.
* At least 3 weeks post major surgery, chemotherapy or radiotherapy \& recovered from all toxicities.
* Expected survival of at least 2 months.
* CNS metastases permitted provided the patient has adequately recovered from radiotherapy includes stereotactic therapy) or surgery.
* Adequate renal function: serum creatinine ≤1.8 mg/dl \&/or CrCl \>50 cc/min

Eligibility According to Liver Function:

AST:

\</= 1.5 ULN-Docetaxel; \</= 2.5 ULN-Pemetrexed (Liver parameters to be used for pemetrexed in the absence of proven or radiographically suspected liver metastases.); \</= 5.0 ULN-Pemetrexed (Liver parameters to be used for pemetrexed only in the presence of proven or radiographically suspected liver metastases.)

Alk Phosphatase:

\</= 2.5 ULN-Docetaxel; \</= 2.5 ULN-Pemetrexed (Liver parameters to be used for pemetrexed in the absence of proven or radiographically suspected liver metastases.); \</= 5.0 ULN-Pemetrexed (Liver parameters to be used for pemetrexed only in the presence of proven or radiographically suspected liver metastases.)

Total Bilirubin:

\</= 1.5 ULN-Docetaxel; \</= 1.5 ULN-Pemetrexed (Liver parameters to be used for pemetrexed in the absence of proven or radiographically suspected liver metastases.); \</= 2.5 ULN-Pemetrexed (Liver parameters to be used for pemetrexed only in the presence of proven or radiographically suspected liver metastases.)

* Adequate hematologic function: ANC≥1500/mm3 \& platelets ≥100,000/mm3
* Female patients cannot be pregnant and must use contraception if of childbearing age
* Lactating women are excluded.
* Peripheral neuropathy must be CTC grade ≤2
* Patients must not currently be on non-steroidal anti-inflammatory agents or other COX-2 inhibitors (Must be off for at least ≤7 days)
* Written informed consent.

Exclusion Criteria:

* More than two prior chemotherapy regimens for recurrent or relapsed NSCLC.
* COX Independent as defined by change in urinary PGE-M levels following a "run-in" phase of celecoxib.
* Previous treatment with both docetaxel and pemetrexed
* History of greater than grade 2 allergic reaction to celecoxib or any other non-steroid anti-inflammatory agent including aspirin, ibuprofen, or indomethacin.
* History of allergy to compounds containing boron or mannitol.
* History of allergy to sulfonamides.
* Concomitant use of Warfarin, but low dose Coumadin allowed for port prophylaxis
* Recent (past 4 weeks) coronary artery bypass graft (CABG) surgery.
* Inadequate organ function:
* Serum creatinine ≥1.8 mg/dl or a calculated CrCl \<45 cc/min.
* AST \>1.5 upper limits of normal (ULN); alkaline phosphatase \>2.5 ULN; \& bilirubin \>1.5 ULN
* ANC\<1500/mm3 \& platelets \<100,000/mm3
* Active pregnancy or inability or unwillingness to employ appropriate contraception.
* Small cell carcinoma histology.
* Prior malignancy within 5 years of diagnosis of NSCLC. Exceptions include basal cell or non-metastatic squamous cell carcinomas of the skin, cervical carcinoma in situ or FIGO stage I cervical carcinoma, or other cancer history considered not clinically significant by the principal investigator.